Biohaven Pharma (BHVN) Misses Q2 EPS by 49c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.23), $0.49 worse than the analyst estimate of ($2.74). Revenue for the quarter came in at $92.93 million versus the consensus estimate of $78.13 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
• CrowdStrike Holdings Inc. (CRWD) Tops Q1 EPS by 3c, Offers Guidance